ALEXION PHARMACEUTICALS INC

Form 4 July 30, 2014

share

July 30, 201	14										
FORM	Л 4							OMB AF	PROVAL		
UNITED STATES SECURITIES AND EXCHANGE COMMISSION							OMB	3235-0287			
Check tl	his hox		Washing	ton, D.C	20549			Number:			
if no lon	nger		GHANGE C		EELOI		NEDGUID OF	Expires:	January 31, 2005		
subject t		MENT OF				AL OW	NERSHIP OF	Estimated a			
	Section 16. SECURITIES								s per		
Form 4 Form 5			.: 16()	C.1 C	• , •	г 1	4 . 61024	response	0.5		
obligatio							ge Act of 1934,				
may cor	ntinue.		of the Investr	_	-	•	f 1935 or Section	1			
See Inst	ruction	30(11) 0	of the mivesti	iciit Coii	ipany A	Ct 01 19	+0				
1(b).											
(Print or Type	Responses)										
	Address of Reporting	Person *	2. Issuer Nam	e and Tick	er or Trac	ling	5. Relationship of	Reporting Pers	on(s) to		
BELL LEC	ONARD	5	Symbol				Issuer				
			ALEXION F		CEUT	ICALS	(Chec	Check all applicable)			
]	INC [ALXN]			(Chec.	к ан аррисамс)			
(Last)	(First) ((Middle)	3. Date of Earli	est Transac	tion		_X_ Director		Owner		
			(Month/Day/Ye 07/28/2014	ar)			_X_ Officer (give below)	title Othe below)	r (specify		
C/O ALEX				ociow)	CEO						
	CEUTICALS INC	C, 352									
KNOTTER	R DRIVE										
	(Street)	4	4. If Amendmen	nt, Date Or	iginal		6. Individual or Jo	int/Group Filin	g(Check		
]	Filed(Month/Day	/Year)			Applicable Line)				
CHECHIDI	F CT 06410						_X_ Form filed by C Form filed by M	One Reporting Per Iore than One Re			
CHESHIKI	E, CT 06410						Person	J			
(City)	(State)	(Zip)	Table I - N	on-Deriva	itive Seci	irities Ac	quired, Disposed of	, or Beneficiall	y Owned		
1.Title of	2. Transaction Date					cquired (A		6.	7. Nature of		
Security (Instr. 3)	(Month/Day/Year)	Execution I any	Date, if Trans Code	actionor Di	sposed of . 3, 4 and		Securities Beneficially	Ownership Form:	Indirect Beneficial		
(IIIsti. <i>3)</i>		(Month/Day			. <i>5</i> , 4 and	3)	Owned	Direct (D)			
		`	, ,				Following	or Indirect	(Instr. 4)		
					(4	A)	Reported Transaction(s)	(I)			
					(or	(Instr 3 and 4)	(Instr. 4)			
C			Code	V Am	ount (O) Prio	e (EEEEE)				
Common											
Stock, par value	07/28/2014		M	105,	600	¢ 17	65 1,137,931	D			
\$.0001 per			M	(1)	Α	. ф1/.	05 1,157,951	D			
share											
Common											
Stock, par	0=1001001				0 (1) =	\$					
value	07/28/2014		S	9,34	8 (1) D		93 1,128,583	D			
\$.0001 per						(2)					

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

Common Stock, par value \$.0001 per share	07/28/2014	S	50,737 (1)	D	\$ 162.01 (3)	1,077,846	D
Common Stock, par value \$.0001 per share	07/28/2014	S	34,768 (1)	D	\$ 162.76 (4)	1,043,078	D
Common Stock, par value \$.0001 per share	07/28/2014	S	8,747 (1)	D	\$ 163.81 (5)	1,034,331	D
Common Stock, par value \$.0001 per share	07/28/2014	S	1,000 (1)	D	\$ 164.72 (6)	1,033,331	D
Common Stock, par value \$.0001 per share	07/28/2014	S	1,000 (1)	D	\$ 166.12 (7)	1,032,331	D
Common Stock, par value \$.0001 per share	07/29/2014	M	1,200 (1)	A	\$ 17.65	1,033,531	D
Common Stock, par value \$.0001 per share	07/29/2014	S	1,200 (1)	D	\$ 164.93 (8)	1,032,331	D
Common Stock, par value \$.0001 per share	07/30/2014	M	20,489 (1)	A	\$ 17.65	1,052,820	D
Common Stock, par value \$.0001 per share	07/30/2014	S	13,679 (1)	D	\$ 165.18 (8)	1,039,141	D
	07/30/2014	S	4,010 (1)	D		1,035,131	D

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

Common Stock, par value \$.0001 per share			\$ 166.42 (9)	
Common Stock, par value 07/30/2014 \$.0001 per share	S	2,800 (1) D	\$ 167.14 1,032,331 (10)	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	Secur Secur Acqu Dispo		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Option to Purchase Common Stock	\$ 17.65	07/28/2014		M		105,600 (1)	04/09/2008	01/09/2018	Common Stock	105,60
Option to Purchase Common Stock	\$ 17.65	07/29/2014		M		1,200 (1)	04/09/2008	01/09/2018	Common Stock	1,200
Option to Purchase Common Stock	\$ 17.65	07/30/2014		M		20,489	04/09/2008	01/09/2018	Common Stock	20,48

Reporting Owners

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				

Reporting Owners 3

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

BELL LEONARD
C/O ALEXION PHARMACEUTICALS INC
352 KNOTTER DRIVE
CHESHIRE, CT 06410

Signatures

/s/ Michael Greco Attorney-in-Fact

07/30/2014

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The transaction is made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$160.42 \$161.42. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$161.42 \$162.42. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$162.42 \$163.42. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$163.43 \$164.43. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$164.44 \$165.44. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$165.84 \$166.84. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$164.90 \$165.90. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$166.91 \$167.91. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$166.98 \$167.98. The price reported in (10) this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 4